INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 12, 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Feb. 12, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a...
INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
February 06, 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as...
INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer’s Disease Program
January 30, 2024 08:00 ET
|
INmune Bio, Inc.
The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the...
INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer
January 02, 2024 08:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
INmune Bio Provides Update Regarding Global Alzheimer’s Phase II Clinical Trial and Clinical Hold Issued by the United States FDA
December 18, 2023 16:01 ET
|
INmune Bio, Inc.
Enrollment in the Company’s Phase II study using XProTM to treat patients with Alzheimer’s Disease with neuroinflammation is accelerating in sites outside the US and the Company is maintaining its...
INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+ Breast Cancer with MUC4 Expression in Poster Presented at San Antonio Breast Cancer Symposium
November 29, 2023 08:00 ET
|
INmune Bio, Inc.
INB03 increases uptake of deruxtecan, the immunotoxin associated with trastuzumab deruxtecan (T-DXd, ENHERTU®), in models of resistant MUC4 expressing HER2 positive breast cancer and increases the...
INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial of XPro™ for Early Alzheimer’s Disease
November 27, 2023 08:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Nov. 27, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company dedicated to advancing treatments that leverage the...
INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in Europe
November 15, 2023 09:00 ET
|
INmune Bio, Inc.
The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive. Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune...
INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update
November 01, 2023 16:10 ET
|
INmune Bio, Inc.
BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...
INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority
October 31, 2023 08:00 ET
|
INmune Bio, Inc.
INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent...